GE unveils industry's first contrast-enhanced mammography biopsy solution.
CHICAGO - In an industry first, GE Healthcare revealed Serena Bright™, its contrast-enhanced mammography solution for biopsy.
The company introduced the product during this year's Radiological Society of North America annual meeting.
The goal, said company representatives, is to add another biopsy option for women who have lesions not identified with mammography or ultrasound. Traditionally, contrast-enhanced biopsy has been performed with the more time-consuming, complex, expensive breast MR. In contrast, Serena Bright offers patients a biopsy in the same room, with the same mammography equipment, and with the same staff as they experience with their screening or diagnostic mammogram.
To identify malignant lesions previously not identified with mammography or ultrasound, Serena Bright uses GE Healthcare’s SenoBright™ HD Contrast Enhanced Spectral Mammography. It pinpoints unusual blood flow areas, helping to localize lesions requiring biopsy. In doing so, the tool can improve a radiologist’s diagnostic confidence and accelerate patient care, representatives said.
Like GE Healthcare’s Senographe Pristina™ system, Serena Bright offers patients the same comfort features, such as rounded edges. In addition, a robotic arm - which operates out of the patient’s field-of-view - automatically positions the needle for the biopsy.
U.S. Food & Drug Administration 510(k) clearance is pending with U.S. availability expected in 2020. To date, Serena Bright has been used in clinics in France and Spain with more than 20 cases completed. Additionally, GE Healthcare is currently partnering with the American College of Radiology to enroll women in a clinical trial that will compare contrast-enhanced mammography biopsy to other biopsy solutions. The trial will also begin in 2020.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.